Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Therapies for Treatment-Resistant Panic Disorder Symptoms
- Conditions
- Panic Disorder
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00118417
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania
- Conditions
- Impulse Control Disorders
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2008-05-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00118014
- Locations
- 🇺🇸
Massachusetts General Hospital - OCD Clinic, Charlestown, Massachusetts, United States
Treatment of Adolescent Suicide Attempters (TASA)
- Conditions
- Suicide, AttemptedDepression
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 120
- Registration Number
- NCT00080158
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Columbia University at the New York State Psychiatric Institute, New York, New York, United States
🇺🇸New York University Child Study Center, New York, New York, United States
Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure
- Conditions
- DepressionHeart Failure, CongestiveChronic Heart Failure
- Interventions
- Drug: PlaceboDrug: Sertraline
- First Posted Date
- 2004-02-24
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Duke University
- Target Recruit Count
- 469
- Registration Number
- NCT00078286
- Locations
- 🇺🇸
Duke Medical Center, Durham, North Carolina, United States
Treatment of Cholestatic Pruritus With Sertraline
- Conditions
- Hepatitis CLiver Cirrhosis, BiliaryPruritus
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Target Recruit Count
- 40
- Registration Number
- NCT00058903
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Improving Retention of Hispanics Receiving Antidepressant Therapy
- Conditions
- DepressionDepressive Disorder
- Interventions
- First Posted Date
- 2003-04-08
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 50
- Registration Number
- NCT00057642
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Study of Pharmacotherapy of Psychotic Depression
- Conditions
- Major Depressive Disorder With Psychotic Features
- Interventions
- First Posted Date
- 2003-03-17
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 259
- Registration Number
- NCT00056472
- Locations
- 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇺🇸Cornell University, New York, New York, United States
Evaluation of Stress Disorders
- Conditions
- Acute Traumatic Stress DisordersPost-Traumatic Stress Disorders
- First Posted Date
- 2002-12-20
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 80
- Registration Number
- NCT00050804
- Locations
- 🇺🇸
National Institute of Mental Health (NIMH), Bethesda, Maryland, United States
Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)
- Conditions
- Dementia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Target Recruit Count
- 30
- Registration Number
- NCT00001777
- Locations
- 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder
- Conditions
- Premenstrual Syndrome
- Interventions
- Other: Treatment as usual (TAU)Drug: Sertraline
- First Posted Date
- 2002-11-13
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Yale University
- Target Recruit Count
- 66
- Registration Number
- NCT00048854
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.